Tag: KDC-MN-356

  • Cetirizine

    Second-generation H1 antihistamine (peripheral)

    A second-generation peripheral H1 antihistamine; the principal active metabolite of hydroxyzine without CNS penetration.

    Abstract

    Cetirizine (2-[2-[4-[(R/S)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy]acetic acid; CAS 83881-51-0; molecular formula C21H25ClN2O3; molecular weight 388.89) is a second-generation H1 antihistamine developed at UCB and approved by the FDA in 1995 (Zyrtec). The compound is the principal active carboxylic acid metabolite of hydroxyzine; the addition of the carboxyl group eliminates blood-brain barrier penetration, producing peripheral H1 antagonism without the central sedating effects of hydroxyzine. H1 selectivity is high; minimal anticholinergic activity. Plasma half-life is approximately 8 hours; minimal hepatic metabolism (excreted largely unchanged renally). The compound has minor sedating effect in approximately 10 to 15 percent of users (slightly more than fexofenadine or loratadine), reflecting some BBB penetration. Approved indications: allergic rhinitis, urticaria, allergic conjunctivitis. Used as the canonical second-generation peripheral H1 antagonist in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.